Cytokinetics, Incorporated CYTK
Regular-session close
After hours · Nov 19, 4:56 PM ET
- YTD
- -19.01%
- 1 year
- -20.57%
5D -1.93 (-3.50%)
- Market cap
- 7.17B
- Revenue (ttm)
- 113.29M
- EPS (ttm)
- -6.03
- Shares out
- 139.30M
- Forward P/E
- -12.16
- YTD return
- -19.01%
- 1-year return
- -20.57%
- 50-day average
- 62.79
- 200-day average
- 69.59
- Enterprise value
- 7.45B
- Volume
- 1.74M
- Avg volume
- 2.02M
- Open
- 51.51
- Previous close
- 51.32
- Day's range
- 50.32 – 52.71
- 52-week range
- 51.32 – 87.26
- Beta
- 0.47
- Analysts
- Strong Buy
- Price target
- 109.58 (+112.9%)
- Earnings date
- Feb 23, 2027
Key statistics
- Price / sales
- 63.28
- Revenue growth
- 2356.50%
- Free cash flow
- -403.33M
- Total cash
- 1.13B
- Total debt
- 1.43B
- Short % of float
- 19.65%
Fundamental scorecard
6 of 25 checks passed on CYTK’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 78.00
- Target (mean)
- 109.58
- Target (high)
- 146.00
- Strong buy7
- Buy13
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate -1.33.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | -1.41 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -1.43 | -1.37 | +0.06 | +4.20% |
| Aug 6, 2026 | Jun 30, 2026 | -1.63 | -1.50 | +0.13 | +7.98% |
| May 5, 2026 | Mar 31, 2026 | -1.67 | -1.67 | 0.00 | 0.00% |
| Feb 24, 2026 | Dec 31, 2025 | -1.48 | -1.50 | -0.02 | -1.35% |
| Nov 5, 2025 | Sep 30, 2025 | -1.59 | -2.55 | -0.96 | -60.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Citigroup | main | Buy | Buy |
| Nov 5, 2026 | Leerink Partners | main | Outperform | Outperform |
| Oct 19, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 31, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cytokinetics.com
News
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics, Incorporated (CYTK) Presents at UBS Global Biopharma Conference 2026 Transcript
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
Cytokinetics' MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market Cytokinetics Presents New Aficamten Data From ACACIA-HCM And FOREST-HCM At HCMS Scientific Sessions 2026
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026 Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105
Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100
Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on CYTK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BHANJI MUNA | Director | Stock Award(Grant) | May 26, 2026 | 26,361 |
| BLUM ROBERT I | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 15, 2026 | 282,710 |
| CALLOS ANDREW | Officer | Conversion of Exercise of derivative security | Aug 30, 2026 | 58,555 |
| HARRINGTON ROBERT ARTHUR | Director | Stock Award(Grant) | Oct 15, 2026 | 22,127 |
| HENDERSON JOHN TANNAHILL | Director | Stock Award(Grant) | Oct 15, 2026 | 78,795 |
| HESSEKIEL JEFFREY J | Officer | Sale | Nov 16, 2026 | 92,837 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.10% | 21,041,152 | 1.08B | Sep 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 13.58% | 18,912,704 | 973.25M | Sep 29, 2026 |
| Wellington Management Group, LLP | 7.60% | 10,590,381 | 544.98M | Sep 29, 2026 |
| Polar Capital Holdings PLC | 6.92% | 9,635,314 | 495.83M | Sep 29, 2026 |
| State Street Corporation | 5.13% | 7,143,229 | 367.59M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.88% | 6,799,536 | 349.90M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 4.51% | 6,285,983 | 323.48M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.55% | 4,952,045 | 254.83M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.10% | 4,314,356 | 222.02M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.51% | 3,491,654 | 179.68M | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.40% | 3,341,262 | 171.94M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.24% | 3,114,802 | 160.29M | Jun 29, 2026 |
